Overexpression of the oncogene C-ERBB-2 in ovarian cancer: A new prognostic factor

Meden, Harald; Marx, D; Rath, Werner; Kron, Martina; Fattahi-Meibodi, A; Hinney, B.; Kühn, Walter; Schauer, A.

doi:10.1016/0959-8049(94)90863-x

Cited by 2 publications

(2 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Slamon et al reported an approximately 20–30% erbB2 overexpression rate in ovarian carcinomas and found that HER2‐gene amplification, as determined by Southern blotting, and erbB2 overexpression, as determined by immunohistochemistry (IHC), significantly correlated with clinical outcome (10) . The association of erbB2 positivity with a worse prognosis has been confirmed also by other immunohistochemical studies (14,15) . However, there is also evidence in support of erbB2 overexpression having no adverse prognostic significance in ovarian cancer (16,17) .…”

mentioning

confidence: 64%

Tissue microarray analysis of EGFR and erbB2 copy number changes in ovarian tumors

Dimova

Zaharieva

Raitcheva

et al. 2006

Int J Gynecol Cancer

View full text Add to dashboard Cite

The objective of this study was to assess the implication of copy number changes of epidermal growth factor receptor (EGFR) and erbB2 genes in the etiology and progression of ovarian tumors. In our study, we used the highly reliable method of fluorescent in situ hybridization, applied on tissue microarray, containing 1006 ovarian tumors from different malignancy, histologic type and grade, and tumor stage, in order to analyze the correlations between gene copy number changes and tumor phenotype. We established copy number changes of erbB2 in 15.30% of malignant ovarian tumors-8.16% amplifications and 7.14% gains. The frequency of EGFR copy number changes was 10.67%-3.65% amplifications and 7.02% gains. EGFR gains occurred with approximately the same frequency in malignant (7.02%), low malignant potential (8.33%), and benign (7.19%) ovarian tumors. ErbB2 amplification was associated with clear cell type of ovarian cancer (P < 0.04). No amplification of EGFR and erbB2 genes was established in tumors with low malignant potency and in benign tumors. Regarding cancer phenotype, there was no statistically significant association between erbB2 copy number changes and histologic grade as well as tumor stage of ovarian cancer. EGFR gains are early events in ovarian tumorigenesis. Our results showed similar frequencies of EGFR gains in different grade tumors, while EGFR amplification increased from grades 1 to 2 to 3.

show abstract

mentioning

confidence: 64%

Tissue microarray analysis of EGFR and erbB2 copy number changes in ovarian tumors

Dimova

Zaharieva

Raitcheva

et al. 2006

Int J Gynecol Cancer

View full text Add to dashboard Cite

show abstract

“…[14] Although whether NACT should be the better treatment for locally advanced cervical cancer (LACC) remained debatable, it has the potential to become a standard of care, even in regions where radiation therapy is available. Today, NACT has been largely used in England, [15] German, [16,17] Italy, [18] Bulgaria, [19] Belgium, [20] China, [21] South Korea, [22] Mexico, [23] and Japan. [24] Different experiences from Europe, Asia, and South America have shown an improved benefit at 5-year survival when using NACT followed by RH or chemoradiation in the LACC cases.…”

Section: Introductionmentioning

confidence: 99%

A Fifteen‐Gene Classifier to Predict Neoadjuvant Chemotherapy Responses in Patients with Stage IB to IIB Squamous Cervical Cancer

et al. 2021

View full text Add to dashboard Cite

Neoadjuvant chemotherapy (NACT) remains an attractive alternative for controlling locally advanced cervical cancer. However, approximately 15-34% of women do not respond to induction therapy. To develop a risk stratification tool, 56 patients with stage IB-IIB cervical cancer are included in 2 research centers from the discovery cohort. Patient-specific somatic mutations led to NACT non-responsiveness are identified by whole-exome sequencing. Next, CRISPR/Cas9-based library screenings are performed based on these genes to confirm their biological contribution to drug resistance. A 15-gene classifier is developed by generalized linear regression analysis combined with the logistic regression model. In an independent validation cohort of 102 patients, the classifier showed good predictive ability with an area under the curve of 0.80 (95% confidence interval (CI), 0.69-0.91). Furthermore, the 15-gene classifier is significantly associated with patient responsiveness to NACT in both univariate (odds ratio, 10.8; 95% CI, 3.55-32.86; p = 2.8 × 10 −5 ) and multivariate analysis (odds ratio, 17.34; 95% CI, 4.04-74.40; p = 1.23 × 10 −4 ) in the validation set. In conclusion, the 15-gene classifier can accurately predict the clinical response to NACT before treatment, representing a promising approach for guiding the selection of appropriate treatment strategies for locally advanced cervical cancer.

show abstract

Overexpression of the oncogene C-ERBB-2 in ovarian cancer: A new prognostic factor

Cited by 2 publications

References 23 publications

Tissue microarray analysis of EGFR and erbB2 copy number changes in ovarian tumors

Tissue microarray analysis of EGFR and erbB2 copy number changes in ovarian tumors

A Fifteen‐Gene Classifier to Predict Neoadjuvant Chemotherapy Responses in Patients with Stage IB to IIB Squamous Cervical Cancer

Contact Info

Product

Resources

About